Pluri (FRA:4DX) Short Interest


FRA:4DX Pluri Inc FRA:4DX
25 GF Score
Price €5.60
GF Value €17.09
! 6 Warning Signs
View Full Analysis

What is Pluri Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:4DX vs VTGN, PTN, CLRB: Short Interest Comparison

For the Biotechnology subindustry, Pluri's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pluri Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's Short Interest distribution charts can be found below:

* The bar in red indicates where Pluri's Short Interest falls into.


FRA:4DX
25GF Score
Pluri Inc FRA:4DX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pluri (FRA:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of €5.60 is trading 67.2% below its estimated GF Value™ of €17.09.

Key valuation signals for FRA:4DX:

  • Short Interest:
  • GF Value™: €17.09 vs. price of €5.60 (67.2% below fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the FRA:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pluri Business Description

Other Exchanges PLUR:USAPLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score

Get the complete analysis for FRA:4DX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.60
Price
€17.09
GF Value